The relevance of drug volume of distribution in antibiotic dosing

Current Pharmaceutical Biotechnology

Volumn 12, Issue 12, 2011, Pages 1996-2001

  Ulldemolins, Marta ^a,b,c   Rello, Jordi ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Critically ill patient; Intensive care unit; Optimal therapy; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFOPERAZONE; CEFTRIAXONE; DAPTOMYCIN; ECHINOCANDIN; ERTAPENEM; ERYTHROMYCIN; FLUCLOXACILLIN; FUSIDIC ACID; GENTAMICIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; METRONIDAZOLE; POLYMYXIN; POLYPEPTIDE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ADIPOSE TISSUE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BURN; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TARGETING; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; HUMAN; HYDROPHILICITY; HYPOALBUMINEMIA; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; OBESITY; PHYSICAL CHEMISTRY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADIPOSE TISSUE; ANTI-BACTERIAL AGENTS; BODY WATER; CRITICAL ILLNESS; HUMANS;

EID: 84855222461     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798808365     Document Type: Article

References (58)

1. Roberts, J. A.; Lipman, J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med., 2009, 37 (3), 840-851.
2. Paterson, D. L. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy. Clin. Infect. Dis., 2008, 47 (Suppl 1), S14-20.
3. Rice, T. W.; Bernard, G. R. Therapeutic intervention and targets for sepsis. Annu. Rev. Med., 2005, 56, 225-248.
4. Rello, J.; Gallego, M.; Mariscal, D.; Sonora, R.; Valles, J. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med., 1997, 156 (1), 196-200.
5. Kollef, M. H.; Sherman, G.; Ward, S.; Fraser, V. J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest, 1999, 115 (2), 462-474.
6. Garnacho-Montero, J.; Garcia-Garmendia, J. L.; Barrero-Almodovar, A.; Jimenez-Jimenez, F. J.; Perez-Paredes, C.; Ortiz-Leyba, C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med., 2003, 31 (12), 2742-2751.
7. Kumar, A.; Roberts, D.; Wood, K. E.; Light, B.; Parrillo, J. E.; Sharma, S.; Suppes, R.; Feinstein, D.; Zanotti, S.; Taiberg, L.; Gurka, D.; Cheang, M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med., 2006, 34 (6), 1589-1596.
8. Pea, F.; Viale, P.; Furlanut, M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin. Pharmacokinet, 2005, 44 (10), 1009-1034.
9. Power, B. M.; Forbes, A. M.; van Heerden, P. V.; Ilett, K. F. Pharmacokinetics of drugs used in critically ill adults. Clin. Pharmacokinet, 1998, 34 (1), 25-56.
10. van der Poll, T.; Opal, S. M. Host-pathogen interactions in sepsis. Lancet Infect. Dis., 2008, 8 (1), 32-43.
11. Plank, L. D.; Hill, G. L. Similarity of changes in body composition in intensive care patients following severe sepsis or major blunt injury. Ann. N Y. Acad. Sci., 2000, 904, 592-602.
12. Marik, P. E. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth. Intensive Care, 1993, 21 (2), 172-173.
13. Kitzes-Cohen, R.; Farin, D.; Piva, G.; De Myttenaere-Bursztein, S. A. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int. J. Antimicrob. Agents, 2002, 19 (2), 105-110.
14. Joynt, G. M.; Lipman, J.; Gomersall, C. D.; Young, R. J.; Wong, E. L.; Gin, T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J. Antimicrob. Chemother., 2001, 47 (4), 421-429.
15. Burkhardt, O.; Kumar, V.; Katterwe, D.; Majcher-Peszynska, J.; Drewelow, B.; Derendorf, H.; Welte, T. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J. Antimicrob. Chemother., 2007, 59 (2), 277-284.
16. del Mar Fernandez de Gatta Garcia, M.; Revilla, N.; Calvo, M. V.; Dominguez-Gil, A.; Sanchez Navarro, A. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med., 2007, 33 (2), 279-285.
17. Roberts, J. A.; Roberts, M. S.; Robertson, T. A.; Dalley, A. J.; Lipman, J. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Crit. Care Med., 2009, 37 (3), 926-933.
18. Roberts, J. A.; Kirkpatrick, C. M.; Roberts, M. S.; Robertson, T. A.; Dalley, A. J.; Lipman, J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J. Antimicrob. Chemother., 2009, 64 (1), 142-150.
19. Buerger, C.; Plock, N.; Dehghanyar, P.; Joukhadar, C.; Kloft, C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob. Agents Chemother., 2006, 50 (7), 2455-2463.
20. Finfer, S.; Bellomo, R.; McEvoy, S.; Lo, S. K.; Myburgh, J.; Neal, B.; Norton, R. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ Clin. Res., 2006, 333 (7577), 1044.
21. Friedrich, L. V.; White, R. L.; Kays, M. B.; Brundage, D. M.; Yarbrough, D3rd. Aztreonam pharmacokinetics in burn patients. Antimicrob. Agents Chemother., 1991, 35 (1), 57-61.
22. Ulldemolins, M.; Roberts, J.A.; Wallis, S.C.; Rello, J.; Lipman, J. Flucloxacillin dosing in critically ill patients with hypoalbuminemia: special emphasis on unbound pharmacokinetics. J. Antimicrob. Chemother., 2010, 65(8), 1771-1778.
23. Peter, J. D.; Jehl, F.; Pottecher, T.; Dupeyron, J. P.; Monteil, H. Pharmacokinetics of intravenous fusidic acid in patients with cholestasis. Antimicrob. Agents Chemother., 1993, 37 (3), 501-506.
24. Boselli, E.; Breilh, D.; Saux, M. C.; Gordien, J. B.; Allaouchiche, B. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med., 2006, 32 (12), 2059-2062.
25. Burkhardt, O.; Kumar, V.; Katterwe, D.; Majcher-Peszynska, J.; Drewelow, B.; Derendorf, H.; Welte, T. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J. Antimicrob. Chemother., 2007, 59 (2), 277-284.
26. Brink, A. J.; Richards, G. A.; Schillack, V.; Kiem, S.; Schentag, J. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int. J. Antimicrob. Agents, 2009, 33 (5), 432-436.
27. Weinbren, M. J. Pharmacokinetics of antibiotics in burn patients. J. Antimicrob. Chemother., 1999, 44 (3), 319-327.
28. Jaehde, U.; Sorgel, F. Clinical pharmacokinetics in patients with burns. Clin. Pharmacokinet, 1995, 29 (1), 15-28.
29. Dailly, E.; Kergueris, M. F.; Pannier, M.; Jolliet, P.; Bourin, M. Population pharmacokinetics of imipenem in burn patients. Fundam Clin. Pharmacol., 2003, 17 (6), 645-650.
30. Dailly, E.; Pannier, M.; Jolliet, P.; Bourin, M. Population pharmacokinetics of ceftazidime in burn patients. Br. J. Clin. Pharmacol., 2003, 56 (6), 629-634.
31. Bourget, P.; Lesne-Hulin, A.; Le Reveille, R.; Le Bever, H.; Carsin, H. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob. Agents Chemother., 1996, 40 (1), 139-145.
32. Bracco, D.; Landry, C.; Dubois, M. J.; Eggimann, P. Pharmacokinetic variability of extended interval tobramycin in burn patients. Burns, 2008, 34 (6), 791-796.
33. Mohr, J. F. 3rd; Ostrosky-Zeichner, L.; Wainright, D. J.; Parks, D. H.; Hollenbeck, T. C.; Ericsson, C. D. Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob. Agents Chemother., 2008, 52 (5), 1891-1893.
34. Elmadfa, I.; Freisling, H. Nutritional status in Europe: methods and results. Nutr. Rev., 2009, 67 (Suppl 1), S130-134.
35. Cameron, A. J.; Welborn, T. A.; Zimmet, P. Z.; Dunstan, D. W.; Owen, N.; Salmon, J.; Dalton, M.; Jolley, D.; Shaw, J. E. Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med. J. Aust., 2003, 178 (9), 427-432.
36. Catenacci, V. A.; Hill, J. O.; Wyatt, H. R. The obesity epidemic. Clin. Chest Med., 2009, 30 (3), 415-444.
37. Falagas, M. E.; Karageorgopoulos, D. E. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet, 375 (9710), 248-251.
38. Sketris, I.; Lesar, T.; Zaske, D. E.; Cipolle, R. J. Effect of obesity on gentamicin pharmacokinetics. J. Clin. Pharmacol., 1981, 21 (7), 288-293.
39. Bauer, L. A.; Edwards, W. A.; Dellinger, E. P.; Simonowitz, D. A. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur. J. Clin. Pharmacol., 1983, 24 (5), 643-647.
40. Blouin, R. A.; Bauer, L. A.; Miller, D. D.; Record, K. E.; Griffen, W. O. Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother., 1982, 21 (4), 575-580.
41. Vance-Bryan, K.; Guay, D. R.; Gilliland, S. S.; Rodvold, K. A.; Rotschafer, J. C. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob. Agents Chemother., 1993, 37 (3), 436-440.
42. Schrier, R. W. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am. J. Med., 2006, 119 (7 Suppl 1), S47-53.
43. Shemin, D.; Dworkin, L. D. Sodium balance in renal failure. Curr. Opin. Nephrol. Hypertens, 1997, 6 (2), 128-132.
44. Aldaz, A.; Ortega, A.; Idoate, A.; Giraldez, J.; Brugarolas, A. Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer. Ther. Drug Monit., 2000, 22 (3), 250-257.
45. Boscia, J. A.; Korzeniowski, O. M.; Snepar, R.; Kobasa, W. D.; Levison, M. E.; Kaye, D. Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis. Antimicrob. Agents Chemother., 1983, 23 (3), 385-389.
46. el Touny, M.; el Guinaidy, M.; Abdel Barry, M.; Osman, L.; Sabbour, M. S. Pharmacokinetics of aztreonam in patients with liver cirrhosis and ascites. J. Antimicrob. Chemother., 1992, 30 (3), 387-395.
47. Gill, M. A.; Kern, J. W. Altered gentamicin distribution in ascitic patients. Am. J. Hosp. Pharm., 1979, 36 (12), 1704-1706.
48. Lewis, G. P.; Jusko, W. J. Pharmacokinetics of ampicillin in cirrhosis. Clin. Pharmacol. Ther., 1975, 18 (4), 475-484.
49. Barre, J.; Mallat, A.; Rosenbaum, J.; Deforges, L.; Houin, G.; Dhumeaux, D.; Tillement, J. P. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br. J. Clin. Pharmacol., 1987, 23 (6), 753-757.
50. Rothschild, M. A.; Oratz, M.; Zimmon, D.; Schreiber, S. S.; Weiner, I.; Van Caneghem, A. Albumin synthesis in cirrhotic subjects with ascites studied with carbonate-14C. J. Clin. Invest., 1969, 48 (2), 344-350.
51. Lieber, C. S. Relationships between nutrition, alcohol use, and liver disease. Alcohol Res. Health, 2003, 27 (3), 220-231.
52. Pavek, P.; Ceckova, M.; Staud, F. Variation of drug kinetics in pregnancy. Curr. Drug Metab., 2009, 10 (5), 520-529.
53. Liu, P.; Derendorf, H. Antimicrobial tissue concentrations. Infect. Dis. Clin. North. Am., 2003, 17 (3), 599-613.
54. Rowland, M.; Tozer, T. N. Clinical pharmacokinetics. Concepts and applications. Eds.; Lippincott, W. Wilkins: Philadelphia, Pennsylvania, 3rd ed., 1995.
55. Miller, M. E.; Cosgriff, J. M.; Forbes, G. B. Bromide space determination using anion-exchange chromatography for measurement of bromide. Am. J. Clin. Nutr., 1989, 50 (1), 168-171.
56. Chumlea, W. C.; Guo, S. S. Bioelectrical impedance and body composition: present status and future directions. Nutr. Rev., 1994, 52 (4), 123-131.
57. Jacob, M.; Conzen, P.; Finsterer, U.; Krafft, A.; Becker, B. F.; Rehm, M. Technical and physiological background of plasma volume measurement with indocyanine green: a clarification of misunderstandings. J. Appl. Physiol., 2007, 102 (3), 1235-1242.
58. Drusano, G. L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev., 2004, 2 (4), 289-300.